Overview
e184 is a venture capital investor focusing on HealthTech, FinTech, and SaaS in the United States, providing capital to startups to help them grow. It uses a multi-stage VC model, investing equity across early to late stages and aiming for exits such as IPOs or acquisitions, guided by leadership that coordinates capital allocation and leverages expertise in payments, banking, crypto, and investments. The firm differentiates itself through its sector focus combined with flexible stages and a willingness to explore additional verticals, using its payments, banking, and crypto know-how to guide portfolio value. Its goal is to deliver high-growth returns for investors by funding innovative startups, supporting their scale, and exiting positions profitably, while continually seeking new opportunities across industries.
Work here?Claim your company
Simplify's Take
What believers are saying
- e184 posted June 2026 hiring for reproductive tech and BCI specialists, signaling active execution.
- Paterna BioSciences cited e184 participation in its October 2024 $6 million seed round.
- The 2026 website and job listings show continued expansion from concept into staffed labs.
What critics are saying
- The original VC positioning conflicts with 2026 biotech operations and suggests identity drift.
- Human reproduction and artificial womb work face severe ethics, regulatory, and hiring friction.
- If BCI, gametogenesis, or ectogenesis fail, e184 loses its entire thesis and investor narrative.
What makes e184 unique
- e184 now builds in vitro gametogenesis, ectogenesis, genome engineering, and non-invasive BCI.
- Its 2026 site frames one integrated biology platform across reproduction, genetics, and cognition.
- Portland-area labs and UK BCI work create unusually deep, physical R&D infrastructure.
Help us improve and share your feedback! Did you find this helpful?